UCB
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
December 8, 2025Research and Development Neurology, UCB, epilepsy
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can significantly reduce the frequency of …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
September 18, 2025Medical Communications, Research and Development Dermatology, UCB, atopic dermatitis, clinical trial
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults with moderate-to-severe atopic dermatitis (AD). …
Rare and severe epilepsies – current treatments and advance therapeutics
August 29, 2025Medical Communications, Research and Development Neurology, UCB, epilepsy, epilepsy treatment, rare epilepsies
The current forms of immunotherapy, how T cell therapy works and what the future holds
UCB presents epilepsy research at American Epilepsy Society Annual Meeting
December 9, 2024Research and Development American Epilepsy Society, Dravet Syndrome, Neurology, UCB, sleep
Belgian-based biopharmaceutical company UCB has announced it will present 32 abstracts at the American Epilepsy Society (AES) Annual Meeting – …
FDA accepts UCB’s sBLA for Bimzelx
April 5, 2024Medical Communications Bimzelx, FDA, Pharmacy, UCB, sBLA
UCB has announced that the US Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application …
Microsoft and UCB collaborate to treat immunological and neurological diseases
February 23, 2021Manufacturing and Production Microsoft, UCB, artificial intelligence
UCB and Microsoft have agreed a new multi-year collaboration to discover new medicines by combining UCB’s drug discovery and development …
UCB syncs up with Roche and Genentech in Alzheimer’s drug deal worth a potential $2bn+
July 30, 2020Research and Development, Sales and Marketing Genentech, Roche, UCB, partnership
UCB Pharma is set to partner up with Roche and Genentech in a development and commercialisation deal focused on its …
UCB’s investigational IL-17A and IL-17F inhibitor outclasses Novartis’ Cosentyx in plaque psoriasis
July 24, 2020Medical Communications, Research and Development Cosentyx, UCB, pharma, psoriasis
UCB has revealed promising new data from a head-to-head trial pitting the company’s IL-17A and IL-17F inhibitor bimekizumab against Novartis’ …
UCB to invest £1 billion into UK R&D
December 6, 2018Manufacturing and Production, Research and Development R&D, UCB, UK, brussels, investment, research
The Brussels-based multinational UCB will invest £1 billion into UK research and development, according to the government’s Life Sciences Sector …
NICE approves Cimzia but blocks Ilumetri in treatment of psoriasis
December 4, 2018Manufacturing and Production, Sales and Marketing Almirall, Cimzia, Ilumetri, NICE, UCB, UK, pharma, psoriasis
UK drug watchdog NICE has announced two new recommendations relating to medicines for the treatment of psoriasis, approving UCB Pharma’s …
UCB and Biogen’s lupus drug falls short at Phase 2b
October 24, 2018Research and Development Biogen, Lupus, UCB, dapirolizumab pegol, pharma, systemic lupus erythematosus, trial falure
The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet …
Working Life: Jean-Christophe Tellier, CEO of UCB Pharma
September 24, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UCB, Working Life, feature
Just as his company announced robust H1 2018 financials, UCB’s Jean-Christophe Tellier spoke to Pharmafocus to share his experiences of …
Top Ten most popular articles on Pharmafile.com this week
September 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jobs, Novartis, Novo Nordisk, Senate, UCB, manufacturing, opioid crisis, top 10
Manufacturing took a hit this week as Novo Nordisk announced the loss of 400 jobs while Novartis made the move …
UCB brings promising plaque psoriasis data to EADV 2018
September 14, 2018Medical Communications, Research and Development EADV 2018, UCB, pharma, psoriasis
UCB has joined in on the wave of new psoriasis data emerging from the European Academy of Dermatology and Venereology …
EMA approves Cimzia for use in treating plaque psoriasis
July 2, 2018Sales and Marketing Cimzia, EMA, UCB, indication, pharmaceutical
The Brussels-based pharmaceutical company UCB has announced that the European Medicines Agency (EMA) has approved a label extension for Cimzia …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
